GlucoTrack (GCTK) 10-K 31 Mar 23 2022 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 28, 2023	Jun. 30, 2022
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	000-54785
Entity Registrant Name	GLUCOTRACK, INC.
Entity Central Index Key	0001506983
Entity Tax Identification Number	98-0668934
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	301 Route 17 North
Entity Address, Address Line Two	Suite 800
Entity Address, City or Town	Rutherford
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07070
City Area Code	201
Local Phone Number	842-7715
Title of 12(b) Security	Common stock, par value $0.001 per share
Trading Symbol	GCTK
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 3,930,000
Entity Common Stock, Shares Outstanding		15,503,632
Documents Incorporated by Reference	None, except as noted for Part III information in the Company’s Definitive Schedule 14A or Form 10-K/A to be filed on or before April 30, 2023
ICFR Auditor Attestation Flag	false
Auditor Firm ID	1375
Auditor Name	FAHN KANNE & CO. GRANT THORNTON ISRAEL
Auditor Location	Tel-Aviv, Israel
Common Stock [Member]
Title of 12(b) Security	Common Stock

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current Assets
Cash and cash equivalents (Note 2H)	$ 2,312	$ 6,062
Other current assets	67	43
Total current assets	2,379	6,105
Operating lease right-of-use assets, net		40
Property and equipment, net (Note 3)	40	69
Restricted cash (Note 2H)	19	51
TOTAL ASSETS	2,438	6,265
Current Liabilities
Accounts payable	672	631
Operating lease liabilities, current		23
Other current liabilities (Note 4)	341	229
Total current liabilities	1,013	883
Non-current Liabilities
Loans from stockholders (Note 5)	195	210
Operating lease liabilities, non-current		17
Total non-current liabilities	195	227
Total liabilities	1,208	1,110
Commitments and contingent liabilities (Note 6)
Stockholders’ Equity
Common Stock of $ 0.001 par value (“Common Stock”):500,000,000 shares authorized; 15,500,730 and 15,470,402 shares issued and outstanding as of December 31, 2022 and 2021, respectively	15	15
Additional paid-in capital	103,095	102,612
Receipts on account of shares	4
Accumulated other comprehensive income (loss)	17	(6)
Accumulated deficit	(101,901)	(97,466)
Total stockholders’ equity	1,230	5,155
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 2,438	$ 6,265

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	15,500,730	15,470,402
Common stock, shares outstanding	15,500,730	15,470,402

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Research and development expenses (Note 8)	$ 1,967	$ 1,810
Marketing expenses (Note 9)		139
General and administrative expenses (Note 10)	2,465	2,091
Total operating expenses	4,432	4,040
Operating loss	4,432	4,040
Other expense	14	53
Financing income, net	(11)	(26)
Loss for the year	4,435	4,067
Other comprehensive loss (income):
Foreign currency translation adjustment	(23)	21
Comprehensive loss for the year	$ 4,412	$ 4,088
Loss per share (Basic and Diluted)	$ 0.29	$ 0.26
Weighted average number of common stock outstanding used in computing basic and diluted net loss per share	15,474,660	15,450,824

Consolidated Statements of Chan

Consolidated Statements of Changes In Stockholders' Equity - USD ($) $ in Thousands		Common Stock [Member]	Additional Paid-in Capital [Member]	Receipts on Account of Shares [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020		$ 15	$ 102,351		$ 15	$ (93,399)	$ 8,982
Beginning balance, shares at Dec. 31, 2020		15,462,812
Loss for the year						(4,067)	(4,067)
Other comprehensive income					(21)		(21)
Issuance of restricted shares as compensation towards directors			38				38
Issuance of restricted shares as compensation towards directors, shares	[1]	7,588
Stock-based compensation			223				223
Ending balance, value at Dec. 31, 2021		$ 15	102,612		(6)	(97,466)	5,155
Ending balance, shares at Dec. 31, 2021		15,470,402
Loss for the year						(4,435)	(4,435)
Other comprehensive income					23		23
Issuance of restricted shares as compensation towards directors			44	4			48
Issuance of restricted shares as compensation towards directors, shares	[1]	17,223
Stock-based compensation			439				439
Stock-based compensation, shares		13,105
Ending balance, value at Dec. 31, 2022		$ 15	$ 103,095	$ 4	$ 17	$ (101,901)	$ 1,230
Ending balance, shares at Dec. 31, 2022		15,500,730
[1]Less than 1 thousand.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Loss for the year	$ (4,435)	$ (4,067)
Adjustments to reconcile loss for the year to net cash used in operating activities:
Depreciation	23	42
Capital loss from sale of property and equipment	1	42
Stock-based compensation	439	223
Issuance of restricted shares as compensation to directors	48	38
Linkage difference on principal of loans from stockholders	11	6
Changes in assets and liabilities:
Decrease in accounts receivable		68
Decrease in inventory		293
Decrease (increase) in other current assets	(28)	15
Increase (Decrease) in accounts payable	74	(257)
Increase (Decrease) in other current liabilities	138	(172)
Net cash used in operating activities	(3,729)	(3,769)
Cash flows from investment activities:
Proceeds from sale of property and equipment	2	4
Purchase of property and equipment	(1)	(5)
Net cash provided by (used in) investment activities	1	(1)
Effect of exchange rate changes on cash and cash equivalents	(54)	(2)
Change in cash, cash equivalents, and restricted cash	(3,782)	(3,772)
Cash, cash equivalents, and restricted cash at beginning of the year	6,113	9,885
Cash, cash equivalents, and restricted cash at end of the year	$ 2,331	$ 6,113

GENERAL

GENERAL	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	NOTE 1 – GENERAL A. GlucoTrack Inc. (the “Company”) was incorporated on May 18, 2010 under the laws of the State of Delaware. The Company is a medical device company, focuses on the design, development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes. To date, the Company developed indirectly through its wholly owned subsidiary, A.D. Integrity Applications Ltd. (the “Integrity Israel”), a non-invasive glucose monitor, the GlucoTrack® glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, cost and difficulty of conventional (invasive) spot finger stick devices. The first generation (“GlucoTrack 1.0”) utilizes a combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one’s earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. Currently, the Company is developing directly its new generation (“GlucoTrack 2.0”) which utilizes substantially identical underlying sensor technology and which is expected to be based on a completely wireless sensor to be clipped on the earlobe. GlucoTrack 2.0 is designed to eliminate the handheld unit and is expected to transmit results directly to a user’s smartphone. The Company and Integrity Israel are considered collectively as the “Group” In connection with its application to list its shares on Nasdaq Capital Market (“NASDAQ”), as detailed below, on August 13, 2021, the Company effected a reverse split of its Common Stock in a ratio of 1 for 13 On December 8, 2021, the Company announced that its shares of common stock were approved for listing on the Nasdaq Capital Market (“NASDAQ”). Trading on NASDAQ commenced on December 10, 2021 under its existing trading symbol, IGAP. On March 14, 2022, the Company announced that it has completed its corporate name and ticker symbol change on the Nasdaq Capital Market from IGAP to GCTK, effective at the commencement of trading on March 14, 2022. On October 07, 2022, the Company entered into an agreement with its Chief Executive Officer under which intellectual property was purchased to be used for newly acquired continuous glucose monitoring (CGM) technology which is a multi-year implantable CGM targeting Type 1 patients and Type 2 patients on insulin therapy. The technology is in a feasibility assessment phase using bech testing and simulated data. Upon success, the project will migrate into development of a prototype implantable system for evaluation in animal studies. The goal of the implantable CGM technology is to provide a minimum of two years of CGM data without requiring the patient to have a wearable device, unlike current technology available in the market ( see On November 22, 2022, Nasdaq provided notice that pursuant to Nasdaq Listing Rule 5550(b)(1), the Company is required to maintain a minimum of $ 2,500 GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.) NOTE 1 – GENERAL (cont.) B. Going concern uncertainty To date, the Company has not yet generated significant revenues from selling of GlucoTrack 1.0 product. In addition, development and commercialization of GlucoTrack 2.0 product is expected to require substantial expenditures and therefore the Company is dependent upon external sources for financing its operations. As of December 31, 2022, the Company has incurred accumulated deficit of $ 101,901 2,312 The Company plans to finance its operations through the sale of equity and/or debt securities (including shelf registration statement on Form S-3 that was declared effective on September 27, 2021 by the Securities and Exchange Commission (SEC) and which allows the Company to register up to $ 100,000 The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. C. Effect of the spread of the Coronavirus on the Company During the year ended December 31, 2022, there were no material adverse impacts on the consolidated financial statements. The duration, scope and effects of the ongoing COVID-19 pandemic, government and other third-party responses to it, the related macroeconomic effects, and the extent of its impact on the Company’s operational and financial performance will depend on future developments. As events continue to evolve and additional information becomes available, the Company’s estimates and assumptions may change in future periods. GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (US GAAP). A. Use of estimates in the preparation of financial statements The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reported periods. Actual results could differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to evaluation of going concern. B. Functional currency The functional currency of the Company is the US dollar, which is the currency of the primary economic environment in which it operates. In accordance with ASC 830, “Foreign Currency Matters” (ASC 830), balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing at the applicable balance sheet date. For foreign currency transactions included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used. Gains or losses arising from changes in the exchange rates used in the translation of such transactions are carried as financing income or expenses. The functional currency of Integrity Israel is the New Israeli Shekel (“NIS”) and its financial statements are included in consolidation, based on translation into US dollars. Accordingly, assets and liabilities were translated from NIS to US dollars using year-end exchange rates, and income and expense items were translated at average exchange rates during the year. Gains or losses resulting from translation adjustments are reflected in stockholders’ equity, under “accumulated other comprehensive income (loss)”. SCHEDULE OF OFFICIAL EXCHANGE RATE 2022 2021 Official exchange rate of NIS 1 to US dollar 0.284 0.321 Increase (decrease) of the official exchange rate of NIS 1 to US dollar during the year: ( 11.62 )% 3.22 % C. Principles of consolidation The consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany balances and transactions have been eliminated in consolidation. D. Cash and cash equivalents The Group considers all short-term investments, which are highly liquid investments with original maturities of three months or less at the date of purchase, to be cash equivalents. GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.) NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.) E. Business Combinations and Assets Acquisitions When the Company acquires net assets that do not constitute a business, as defined under ASU 2017-01 Business Combinations (Topic 805) Clarifying the Definition of a Business (such when there is no substantive process in the acquired entity), no goodwill is recognized and acquired In-Process Research and Development intangible asset (“IPR&D”) to be used in research and development projects which have been determined not to have alternative future use, is expensed immediately. Contingent consideration related to asset acquisition that will be paid subject to the achievement of performance milestones, which are outside the control of the Company, is recognized when the contingency is resolved or when it is considered as probable and reasonably estimable under ASC 450, Contingencies. During the reported periods, the Company was not involved in any Business Combinations transaction (see also Note 6D). F. Property and equipment, net 1. Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. When an asset is retired or otherwise disposed of, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in the statements of operations. 2. Rates of depreciation: SCHEDULE OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION % Computers 33 Furniture and office equipment 7 15 G. Impairment of long-lived assets The Group’s long-lived assets are reviewed for impairment in accordance with ASC 360, “Property, Plant and Equipment”, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. To date the Group did not incur any material impairment losses related to long lived assets. GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.) NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.) H. Cash and Cash Equivalents and Restricted cash Restricted cash is invested in certificates of deposit, which are used to secure Integrity Israel’s obligations in respect of its headquarters lease and credit card (See also Note 6C). For presentation of statement of cash flows purposes, restrict cash balances are included with cash and cash equivalents, when reconciling the reported period total amounts. SCHEDULE OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS 2022 2021 In thousand of US dollars December 31 December 31 2022 2021 Cash and cash equivalents $ 2,312 $ 6,062 Restricted cash $ 19 $ 51 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 2,331 $ 6,113 I. Income tax The Group accounts for income taxes in accordance with ASC 740, “Income Taxes”. Accordingly, deferred income taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and the tax bases of assets and liabilities under the applicable tax law. Deferred tax balances are computed using the enacted tax rates expected to be in effect when these differences reverse. Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized. The Group accounts for uncertain tax positions in accordance with ASC Topic 740-10, which prescribes detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise’s financial statements. According to ASC Topic 740-10, tax positions must meet a more- likely-than-not recognition threshold. The Group’s accounting policy is to classify interest and penalties relating to uncertain tax positions under income taxes, however the Group did not recognize such items in its fiscal 2022 and 2021 financial statements and did not recognize any liability with respect to unrecognized tax position in its balance sheet. GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.) NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.) J. Liability for employee rights upon retirement Integrity Israel’s liability for employee rights upon retirement with respect to its Israeli employees was calculated pursuant to the Israeli Severance Pay Law, based on the most recent salary of each employee multiplied by the number of years of employment of each such employee as of the balance sheet date. Employees were entitled to one month’s salary for each year of employment, or ratable portion thereof for periods less than one year. Integrity Israel made monthly deposits to insurance policies and severance pay funds. The deposited funds were withdrawn upon the fulfillment of Integrity Israel’s severance obligations pursuant to Israeli severance pay laws or labor agreements with its employees. The value of the deposited funds was based on the cash surrender value of these policies, and includes immaterial profits or losses. Commencing in 2011, Integrity Israel’s agreements with its Israeli employees are in accordance with Section 14 of the Severance Pay Law. Payments in accordance with Section 14 release the employer from any future severance payments in respect of those employees. Related obligations and liabilities under Section 14 are not recorded as an asset or as a liability in the Company’s balance sheet. For the year ended December 31, 2022, and 2021, severance expenses have been recorded in total amount of $ 27 43 K. Research and development expenses Research and development expenses are charged to operations as incurred. L. Royalty-bearing grants Royalty-bearing grants from the Israeli Innovation Authority (IIA) to fund approved research and development projects are recognized at the time Integrity Israel is entitled to such grants, on the basis of the costs incurred and reduce research and development costs. To date, the cumulative research and development grants received by Integrity Israel from IIA amounted to $ 93 GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.) NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.) M. Basic and diluted loss per share Basic loss per share is computed by dividing the loss for the period applicable for Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. In computing, diluted loss per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon the exercise of options or warrants issued or granted using the “treasury stock method”, if the effect of each of such financial instruments is dilutive. In computing diluted loss per share, the average stock price for the period is used in determining the number of common stock assumed to be purchased from the exercise of stock options or stock warrants. Shares that will be issued upon exercise of all stock options and stock warrants, have been excluded from the calculation of the diluted net loss per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as a result of the exercise or conversion of these instruments was anti-dilutive An amount of 6,614,654 6,404,238 N. Stock-based compensation The Group measures and recognizes the compensation expense for all equity-based payments to employees based on their estimated fair values in accordance with ASC 718, “Compensation-Stock Compensation”. Share-based payments including grants of stock options are recognized in the consolidated statement of operations and comprehensive loss as an operating expense based on the fair value of the award at the date of grant. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model. The Group has expensed compensation costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit service period when a performance condition affects the vesting, and it is considered probable that the performance condition will be achieved. Commencing January 1, 2019, following the adoption of ASU 2018-07, which aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payments to employees (with certain exceptions), share-based payments to non-employees are accounted in accordance with ASC 718. GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.) NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.) O. Fair value of financial instruments ASC Topic 825-10, “Financial Instruments” defines financial instruments and requires disclosure of the fair value of financial instruments held by the Group. The Group considers the carrying amount of cash and cash equivalents, restricted cash, accounts receivable, other current assets, accounts payable and other current liabilities balances, to approximate their fair values due to the short-term maturities of such financial instruments. ASC Topic 825-10, establishes the following fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2 - Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. Level 3 - Unobservable inputs are used when little or no market data is available. Level 3 inputs are considered as the lowest priority under the fair value hierarchy. The fair value of the financial instruments included in the working capital of the Group (cash and cash equivalents, accounts payable and other current assets and liabilities) approximates their carrying value. The Group did not estimate the fair value of the loans received from stockholders since their repayment schedule has not yet been determined. P. Concentrations of credit risk Financial instruments that potentially subject the Group to concentrations of credit risk consist primarily of cash and cash equivalents, and restricted cash. Cash and cash equivalents and restricted cash are deposited with major banks in United States. Management believes that such financial institutions are financially sound, accordingly, minimal credit risk exists with respect to these financial instruments. The Group does not have any significant off-balance-sheet concentration of credit risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements. Q. Contingencies The Group records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred. R. Warrants with Down-Round Protection Following the application of Accounting Standard Update (ASU) No. 2017-11, “Earnings Per Share” (ASU 2017-11), the Company disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. Based on its evaluation, management has determined that such warrants with Down-Round Protection are eligible for equity classification. In accordance with the provisions of ASU 2017-11, upon the occurrence of an event that triggers a down round protection (i.e., when the exercise price of the warrants is adjusted downward because of the down round feature), the effect is accounted for as a deemed dividend and as a reduction of income available to common shareholders for purposes of basic earnings per share (EPS) calculation. S. Modification of equity-classified contracts The modification or exchange of equity-classified contracts, such as warrants that were classified as equity before the modification or exchange and remained eligible for equity classification after the modification, is accounted for in a similar manner to a modification of stock-based compensation. Accordingly, the incremental fair value from the modification or exchange (the change in the fair value of the instrument before and after the modification or exchange) is recognized as a reduction of retained earnings of increase of accumulated deficit as a deemed dividend. Modifications or exchanges that result in a decrease in the fair value of an equity-classified share-based payment awards are not recognized. In addition, the amount of the deemed dividend is also recognized as an adjustment to earnings available to common shareholders for purposes of calculating earnings per share. GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.) NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.) T. Operating Lease The Company applies ASC Update 2016-02, Leases (Topic 842) under which the Company determines if an arrangement is a lease at inception. Under Topic 842, arrangements meeting the definition of a lease are classified as operating or financing leases. A classification of a lease is determined based on the following criteria: 1. The lease transfers ownership of the underlying asset to the lessee by the end of the lease term. 2. The lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise. 3. The lease term is for the major part of the remaining economic life of the underlying asset ( Generally, 75% or more of the remaining economic life of the underlying assets 4. The present value of the sum of the lease payments and any residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset ( Generally, 90% or more of the fair value of the underlying asset 5. The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. If any of the above criteria are met, the lease is classified as a finance lease. Otherwise, the lease is classified as an operating lease. Leases are recorded on the consolidated balance sheet as both a right of use asset and a lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset results in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred. The Company also elected the short-term lease recognition exemption for all leases that qualify (leases with a term shorter than 12 In 2022, the Company terminated its lease agreement for vehicles, as the senior employees in Israel has resigned from the Company, and respectively have returned the vehicles to the lease dealership. As of December 31, 2022, the Company is subject to several non-cancelable lease agreements for workspaces for use in its operations, which are classified as operating leases. GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)

PROPERTY AND EQUIPMENT, NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT, NET	NOTE 3 – PROPERTY AND EQUIPMENT, NET SCHEDULE OF PROPERTY AND EQUIPMENT, NET Property and Equipment In thousand of US dollars December 31, 2022 December 31, 2021 Computers 224 306 Furniture and office equipment 70 183 Property and equipment, gross 294 489 Less – accumulated depreciation (254 ) (420 ) Property and equipment, net 40 69 During the years ended December 31, 2022 and 2021, depreciation expenses have been recorded in total amount of $ 23 42

OTHER CURRENT LIABILITIES

OTHER CURRENT LIABILITIES	12 Months Ended
	Dec. 31, 2022
Other Liabilities Disclosure [Abstract]
OTHER CURRENT LIABILITIES	NOTE 4 – OTHER CURRENT LIABILITIES SCHEDULE OF OTHER CURRENT LIABILITIES Other Current Liabilities In thousand of US dollars December 31, 2022 December 31, 2021 Employees and related institutions 16 98 Accrued expenses and others 325 131 Total other current liabilities 341 229

LOANS FROM STOCKHOLDERS

LOANS FROM STOCKHOLDERS	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
LOANS FROM STOCKHOLDERS	NOTE 5 LOANS FROM STOCKHOLDERS During the years 2003-2004, Integrity Israel received loans from stockholders (four separate lenders) in a total amount of approximately $ 400 195 The Group will be required to pay the loans, in quarterly installments, commencing on the first quarter following the first fiscal year in which the Group reports net profit in its annual report. At such time, the Group will be required to make quarterly payments equal to 10% As of December 31, 2022, the Group does not expect to make any material repayments during the following 12-month period, if any, and accordingly the entire remaining balance of the loans from stockholders have been presented as non-current liability. GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)

COMMITMENTS AND CONTINGENT LIAB

COMMITMENTS AND CONTINGENT LIABILITIES	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 6 – COMMITMENTS AND CONTINGENT LIABILITIES A. On March 4, 2004, the Israel innovation authority (IIA) provided Integrity Israel with a grant of approximately $ 93 420 3 5% 93 80 As of December 31, 2022, the Group accrued royalties to the IIA in insignificant amounts. B. Since March 2021 Integrity Israel is renting several workspaces at office building in the city Or – Yehoda. According to the lease agreement, Integrity Israel renting those flexible shared workspaces for period shorter than one year. C. On October 7, 2022 (“the Closing Date”), the Company entered into Intellectual Property Purchase Agreement (the “Agreement”) with Paul Goode, which is the Company’s Chief Executive Officer (the “Seller”), under which it was agreed that on and subject to the terms and conditions of the Agreement, at the Closing Date, Seller shall sell, assign, transfer, convey and deliver to the Company, all of Seller’s right, title and interest in and to the following assets, properties and rights (collectively, the “Purchased Assets”): (a) All rights, title, interests in all current and future intellectual property, including, but not limited to patents, trademarks, trade secrets, industry know-how and other IP rights relating to an implantable continuous glucose sensor (collectively, the “Conveyed Intellectual Property”); and (b) All of the goodwill relating to the Purchased Assets. In consideration for the sale by Seller of the Purchased Assets to the Company, at the Closing Date, the Company paid to Seller cash in the amount of one dollar and up to 1,000,000 1,000,000 1.5% 1.5% When the Company acquires net assets that do not constitute a business, as defined under ASU 2017-01 Business Combinations (Topic 805) Clarifying the Definition of a Business (such when there is no substantive process in the acquired entity) the transaction is accounted for as asset acquisition and no goodwill is recognized. The acquired In-Process Research and Development intangible asset (“IPR&D”) to be used in research and development projects which have been determined not to have alternative future use, is expensed immediately. At the Closing Date, it was determined that the asset acquisition represent the purchase of IPR&D with no alternative future use. However, the achievement of each of the performance milestones is considered as contingent event outside the Company’s control and thus the contingent consideration which is equal to the Purchase Price as measured at the Closing Date will be recognized when it becomes probable that each target will be achieved within the reasonable period of time. Such additional contingent consideration will be recognized in subsequent periods if and when the contingency (the achievement of targets) is resolved, or when it will be considered as reasonably estimable under ASC 450, Contingencies. For the period commencing the Closing Date and through December 31, 2022, the Company did not record any amount related to the contingent consideration, relating to any of the aforesaid performance milestones. GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)

COMMON STOCK AND WARRANTS WITH-

COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION	NOTE 7 – COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION A. Description of the rights attached to the Common Stock Each share of Common Stock entitles the holder to one vote, either in person or by proxy, on each matter submitted to the approval of the Company’s stockholders. The holders of Common Stock are not permitted to vote their shares cumulatively. B. Stock-based compensation 1. Plan On January 11, 2010, the Company’s Board of Directors approved and adopted the 2010 Share Incentive Plan (the “Plan”), pursuant to which the Company’s Board of Directors may award share options to purchase the Company’s Ordinary Shares as well as restricted shares, restricted stock units (the “RSU”) and other share-based awards to designated participants. Subject to the terms and conditions of the Plan, the Company’s Board of Directors has full authority in its discretion, from time to time and at any time, to determine (i) the designate participants; (ii) the terms and provisions of the respective award agreements, including, but not limited to, the number of share options to be granted to each optionee, the number of shares to be covered by each share option, provisions concerning the time and the extent to which the share options may be exercised and the nature and duration of restrictions as to the transferability or restrictions constituting substantial risk of forfeiture and to cancel or suspend awards, as necessary; (iii) determine the fair market value of the shares covered by each award; (iv) make an election as to the type of approved 102 Option under Israeli tax law; (v) designate the type of share options; (vi) take any measures, and to take actions, as deemed necessary or advisable for the administration and implementation of the Plan; (vii) interpret the provisions of the Plan and to amend from time to time the terms of the Plan 2. Grant of equity awards to employees A. On February 8, 2021, The Company granted Mr. Erez Ben-Zvi, the then Vice President of Product of the Company, annual award with fair value of NIS 210 65 5.20 1/12 of the RSUs shall vest and become nonforfeitable three months following the Start Date, and an additional 1/12 of the RSUs shall vest and become nonforfeitable at the end of every 3-months period thereafter, provided that the employee continues to be employed by the Company at the applicable date of vesting In June 2022, Erez Ben-Zvi resigned from the Company. Thus, his stock-based compensation was terminated in the last vesting date of April 2022. During the years ended December 31, 2022 and 2021, the Company recorded stock-based compensation expenses (income) of $( 25 76 GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.) NOTE 7 – COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.) B. Stock-based compensation (cont.) 2. Grant of equity awards to employees (cont.) B. In November 2020, the Company granted Mr. Shalom Shushan, the then Chief Technology Officer of the Company, annual award with fair value of NIS 90 28 60 5.20 1/12 of the RSUs shall vest and become nonforfeitable three months following the Start Date, and an additional 1/12 of the RSUs shall vest and become nonforfeitable at the end of every 3-months period thereafter, provided that the Employee continues to be employed by the Company at the applicable date of vesting In May 2022, Shalom Shushan resigned from the Company. Thus, his stock-based compensation was terminated in the last vesting date of May 2022. During the years ended December 31, 2022 and 2021, the Company recorded stock-based compensation expenses (income) of $( 6 22 C. In November 2021, the Company granted Mr. Paul V. Goode, the President and Chief Executive Officer of the Company, options with the fair value of $ 484 1.5% 0.001 328 5.20 In May 2022, the Company grated Mr. Paul V. Goode, a one-time grant of restricted stock of 18,000 During the years ended December 31, 2022 and 2021, the Company recorded stock-based compensation expenses of $ 306 98 D. In December 2021, the Company granted Mr. James p. Thrower, the Vice President Engineering of the Company, options with the fair value of $ 152 1.15% 0.001 262 5.20 During the years ended December 31, 2022 and 2021, the Company recorded stock-based compensation expenses of $ 93 16 E. In October 2022, the Company granted Mr. Mark Tapsak, the Vice President, Sensor Science of the Company, options with the fair value of $ 22 0.75% 0.001 116 5.20 During the year ended December 31, 2022, the Company recorded stock-based compensation expenses of $ 5 GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.) NOTE 7 – COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.) F . The following table presents the Company’s share option activity for employees and members of the Board of Directors of the Company under the Plan, for the years ended December 31, 2022 and 2021: SCHEDULE OF SHARE OPTION ACTIVITY FOR EMPLOYEES AND MEMBERS Number of Share Options Weighted Average Exercise Price Weighted average remaining contractual life Intrinsic value $ (years) $ Outstanding as of December 31, 2020 128,297 64.46 5.42 - Granted 589,933 5.2 2.88 - Forfeited or expired (98,177 ) 64.64 - - Outstanding as of December 31, 2021 620,053 8.05 2.99 - Exercisable as of December 31, 2021 39,223 50.27 4.65 - Number of Share Options Weighted Average Exercise Price Weighted average remaining contractual life Intrinsic value $ (years) $ Outstanding as of December 31, 2021 620,053 8.05 2.99 - Granted 115,857 5.2 2.68 - Forfeited or expired - - - - Outstanding as of December 31, 2022 735,910 7.6 2.1 - Exercisable as of December 31, 2022 245,535 12.4 2.58 - The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the deemed fair value of the Company’s Ordinary Shares on the last day of each of the applicable reported period and the exercise price, multiplied by the number of in-the-money share options) that would have been received by the share option holders had all share options holders exercised their share options on December 31 of each of the reported period. This amount is impacted by the changes in the fair market value of the Company’s Ordinary Share. GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.) NOTE 7 – COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.) G . The outstanding and exercisable share options as of December 31, 2022 have been separated into ranges of exercise prices, as follows: SCHEDULE OF OUTSTANDING AND EXERCISABLE SHARE OPTIONS Exercise price - $ Share options outstanding as of December 31, 2022 Weighted average remaining contractual term Share options exercisable as of December 31, 2022 Weighted average remaining contractual term (years) (years) 100.75 3,846 4.26 3,846 4.26 58.5 26,274 4.18 26,274 4.18 5.2 705,790 2.01 215,415 1.91 735,910 245,535 H . During the years ended December 31, 2022 and 2021, share options have not been exercised into Ordinary Shares. I . The following table presents the assumptions used to estimate the fair values of the share options granted in the reported periods presented: SCHEDULE OF ASSUMPTIONS USED TO VALUE OPTIONS 2022 2021 Year ended December 31 2022 2021 Volatility (%) 72.15 % 49.21 % Risk-free interest rate (%) 2.5 % 2.5 % Dividend yield (%) - - Expected life (years) 3 3 Exercise price ($) 5.2 5.2 Share price ($) 1.89 3.1 4.65 J . As of December 31, 2022, there was $ 186 0.72 GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.) NOTE 7 – COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.) 3. Grant of equity awards to non-employees A. In connection with the 2017 Offering, the Company has issued to Andrew Garrett Inc, who served as a placement agent in fundraising transaction (a) 5 1,062,717 3.354 5 108,305 23.40 5 8,331 46.80 5 8,331 70.20 In connection with February 2020 Offering, the Company has issued to the Andrew Garrett Inc, who served as a placement agent a 5 288,462 5.2 B. In August 2020, advisory agreement was made between the Company and Malcolm McGuire & Assoc. LLC, under which the advisor is providing strategic advisory services, which include, inter alia, interface with the investment community on behalf of the Company, build a database of appropriate brokers and investors, design and implement a plan for both the short and the long-term encouragement of investor interest in the Company and create a compelling perception of the Company within the investment community. The consideration was set as a monthly fee of $ 4 461 6.5 During the years ended December 31, 2022 and 2021, the Company recorded stock-based compensation expenses of $ 9 13 C . On September 12, 2022, the Company signed on Advisory agreement with Andrew Garrett Inc, under which the Company agreed to extend the exercise through July 1, 2026, for all warrants issued pursuant to the Exchange Agreement dated December 31, 2018. The Company accounted for the extension of the warrants exercise period pursuant to ASC 718 as a modification. Accordingly, additional compensation of $ 56 GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.) NOTE 7 – COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (cont.) D . The outstanding and exercisable share options as of December 31, 2022 have been separated into ranges of exercise prices, as follows: SCHEDULE OF OUTSTANDING AND EXERCISABLE SHARE OPTIONS Exercise price - $ Share options outstanding and exercisable December 31, 2022 Weighted average remaining contractual term (years) 70.2 665,411 1.01 46.8 665,411 1.01 23.4 665,411 1.01 6.5 13,398 0.63 5.2 290,679 2.11 3.35 4,068,497 1.56 6,368,807 The total compensation cost related to all of the Company’s equity-based awards recognized during the years ended December 31, 2022 and 2021 was comprised as follows: SCHEDULE OF TOTAL COMPENSATION COST EQUITY BASED AWARDS Research and Development December 31, 2022 December 31, 2021 In thousand of US dollars Research and Development December 31, 2022 December 31, 2021 Research and development 92 38 General and administrative 395 223 Total compensation cost 487 261 GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)

RESEARCH AND DEVELOPMENT EXPENS

RESEARCH AND DEVELOPMENT EXPENSES	12 Months Ended
	Dec. 31, 2022
Research and Development [Abstract]
RESEARCH AND DEVELOPMENT EXPENSES	NOTE 8 – RESEARCH AND DEVELOPMENT EXPENSES SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES Research and Development December 31, 2022 December 31, In thousand of US dollars Research and Development December 31, 2022 December 31, Salaries and related expenses 749 916 Professional fees 1,124 337 Expenses due to slow inventory write-off - 321 Depreciation 20 32 Vehicle maintenance 12 42 Other 62 162 Total Research and Development Expense 1,967 1,810

MARKETING EXPENSES

MARKETING EXPENSES	12 Months Ended
	Dec. 31, 2022
Marketing Expenses
MARKETING EXPENSES	NOTE 9 – MARKETING EXPENSES SCHEDULE OF MARKETING EXPENSE Selling and Marketing December 31, December 31, Salaries and related expenses - 22 Professional fees - 115 Other - 2 Total selling and marketing expense - 139

GENERAL AND ADMINISTRATIVE EXPE

GENERAL AND ADMINISTRATIVE EXPENSES	12 Months Ended
	Dec. 31, 2022
General And Administrative Expenses
GENERAL AND ADMINISTRATIVE EXPENSES	NOTE 10 – GENERAL AND ADMINISTRATIVE EXPENSES SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES In thousand of US dollars General and Administrative December 31, December 31, Salaries and related expenses 617 608 Professional fees 1,281 1,224 Bad debt expense - 59 Vehicle maintenance 8 41 Depreciation 3 10 Insurance 457 97 Other 99 52 Total general and administrative expenses 2,465 2,091 GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.)

INCOME TAX

INCOME TAX	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
INCOME TAX	NOTE 11 – INCOME TAX A. Measurement of results for tax purposes under the Israeli Income Tax (Inflationary Adjustments) Law, 1985 (the “Inflationary Adjustment Law”) Commencing January 1, 2008, the results of operations of Integrity Israel for tax purposes have been measured on a nominal basis. B. Tax assessments For federal, state and local income tax purposes the Company remains open for examination by the tax authorities for the tax years from 2018 through 2021 under the general statute of limitations. Notwithstanding, pursuant and subject to the provisions of article 145 of the Income Tax Ordinance, Integrity Israel’s tax returns that were filed with the tax authority up to and including 2017 are considered final. C. Loss for the year consists of the following: SCHEDULE OF INCOME TAX LOSS FOR THE YEAR 2022 2021 Year ended December 31 2022 2021 Domestic $ 3,528 $ 1,255 Foreign entity (Integrity Israel) 907 2,812 Total loss for the year 4,435 4,067 D. Net operating losses carryforward As of December 31, 2022, the Company had cumulative Net Operating Losses (NOL) carry forward for US federal purposes of approximately $ 14 38.0 E. For the years ended December 31, 2022 and 2021, the main reconciling item is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating losses carried forward and other permanent and temporary differences due to the uncertainty of the realization of such deferred taxes. GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.) NOTE 11 INCOME TAX (cont.) F. Deferred taxes result principally from temporary differences in the recognition of certain revenue and expense items for financial and income tax reporting purposes. Significant components of the Group’s future tax assets are as follows: SCHEDULE OF DEFERRED TAX ASSETS Composition of deferred tax assets: 2022 2021 As of December 31 Composition of deferred tax assets: 2022 2021 Vacation accrual - 6 Research and development credits 174 - Net operating losses carry forwards 11,805 11,654 Net deferred tax asset before deferred tax liabilities and valuation allowance 11,979 11,660 Valuation allowance (11,979 ) (11,660 ) Net deferred tax assets - -

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
SEGMENT INFORMATION	NOTE 12 SEGMENT INFORMATION The Company operates in one All long-lived assets are owned by Integrity Israel which are located in Israel.

RELATED PARTIES

RELATED PARTIES	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTIES	NOTE 13 – RELATED PARTIES A. Andrew Garrett, Inc: On September 12, 2022, the Company signed on advisory agreement with Andrew Garrett Inc., which is controlled by one of member of the Company’s board of directors, Andrew Sycoff. The Company retains advisor on a non-exclusive basis to receive general business advisory services for total monthly consideration of $ 20 56 For the year ended on December 31, 2022, the Company recognized in total expenses of $ 102 B. Intellectual Property Purchase Agreement - See Note 6C C. Loans From Stockholders – See Note 5 D. Tapsak Enterprises LLC, dba Virginia Analytical On October 25, 2022, the Company entered into agreement with Tapsak Enterprises LLC dba Virginia Analytical, which fully owned by Mark Tapsak, who serves as the Vice President of Sensor Science of the Company , 60 For the year ended on December 31, 2022, the Company recognized in total expenses of $ 38

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 14 SUBSEQUENT EVENTS The Company has evaluated all subsequent events through the date when these financial statements were issued to determine if these must be reported. The Company determined that there were no reportable subsequent events to disclose in these financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Use of estimates in the preparation of financial statements	A. Use of estimates in the preparation of financial statements The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reported periods. Actual results could differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to evaluation of going concern.
Functional currency	B. Functional currency The functional currency of the Company is the US dollar, which is the currency of the primary economic environment in which it operates. In accordance with ASC 830, “Foreign Currency Matters” (ASC 830), balances denominated in or linked to foreign currency are stated on the basis of the exchange rates prevailing at the applicable balance sheet date. For foreign currency transactions included in the statement of operations, the exchange rates applicable on the relevant transaction dates are used. Gains or losses arising from changes in the exchange rates used in the translation of such transactions are carried as financing income or expenses. The functional currency of Integrity Israel is the New Israeli Shekel (“NIS”) and its financial statements are included in consolidation, based on translation into US dollars. Accordingly, assets and liabilities were translated from NIS to US dollars using year-end exchange rates, and income and expense items were translated at average exchange rates during the year. Gains or losses resulting from translation adjustments are reflected in stockholders’ equity, under “accumulated other comprehensive income (loss)”. SCHEDULE OF OFFICIAL EXCHANGE RATE 2022 2021 Official exchange rate of NIS 1 to US dollar 0.284 0.321 Increase (decrease) of the official exchange rate of NIS 1 to US dollar during the year: ( 11.62 )% 3.22 %
Principles of consolidation	C. Principles of consolidation The consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany balances and transactions have been eliminated in consolidation.
Cash and cash equivalents	D. Cash and cash equivalents The Group considers all short-term investments, which are highly liquid investments with original maturities of three months or less at the date of purchase, to be cash equivalents. GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.) NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
Business Combinations and Assets Acquisitions	E. Business Combinations and Assets Acquisitions When the Company acquires net assets that do not constitute a business, as defined under ASU 2017-01 Business Combinations (Topic 805) Clarifying the Definition of a Business (such when there is no substantive process in the acquired entity), no goodwill is recognized and acquired In-Process Research and Development intangible asset (“IPR&D”) to be used in research and development projects which have been determined not to have alternative future use, is expensed immediately. Contingent consideration related to asset acquisition that will be paid subject to the achievement of performance milestones, which are outside the control of the Company, is recognized when the contingency is resolved or when it is considered as probable and reasonably estimable under ASC 450, Contingencies. During the reported periods, the Company was not involved in any Business Combinations transaction (see also Note 6D).
Property and equipment, net	F. Property and equipment, net 1. Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. When an asset is retired or otherwise disposed of, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in the statements of operations. 2. Rates of depreciation: SCHEDULE OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION % Computers 33 Furniture and office equipment 7 15
Impairment of long-lived assets	G. Impairment of long-lived assets The Group’s long-lived assets are reviewed for impairment in accordance with ASC 360, “Property, Plant and Equipment”, whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. To date the Group did not incur any material impairment losses related to long lived assets. GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.) NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
Cash and Cash Equivalents and Restricted cash	H. Cash and Cash Equivalents and Restricted cash Restricted cash is invested in certificates of deposit, which are used to secure Integrity Israel’s obligations in respect of its headquarters lease and credit card (See also Note 6C). For presentation of statement of cash flows purposes, restrict cash balances are included with cash and cash equivalents, when reconciling the reported period total amounts. SCHEDULE OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS 2022 2021 In thousand of US dollars December 31 December 31 2022 2021 Cash and cash equivalents $ 2,312 $ 6,062 Restricted cash $ 19 $ 51 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 2,331 $ 6,113
Income tax	I. Income tax The Group accounts for income taxes in accordance with ASC 740, “Income Taxes”. Accordingly, deferred income taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and the tax bases of assets and liabilities under the applicable tax law. Deferred tax balances are computed using the enacted tax rates expected to be in effect when these differences reverse. Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized. The Group accounts for uncertain tax positions in accordance with ASC Topic 740-10, which prescribes detailed guidance for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise’s financial statements. According to ASC Topic 740-10, tax positions must meet a more- likely-than-not recognition threshold. The Group’s accounting policy is to classify interest and penalties relating to uncertain tax positions under income taxes, however the Group did not recognize such items in its fiscal 2022 and 2021 financial statements and did not recognize any liability with respect to unrecognized tax position in its balance sheet. GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.) NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
Liability for employee rights upon retirement	J. Liability for employee rights upon retirement Integrity Israel’s liability for employee rights upon retirement with respect to its Israeli employees was calculated pursuant to the Israeli Severance Pay Law, based on the most recent salary of each employee multiplied by the number of years of employment of each such employee as of the balance sheet date. Employees were entitled to one month’s salary for each year of employment, or ratable portion thereof for periods less than one year. Integrity Israel made monthly deposits to insurance policies and severance pay funds. The deposited funds were withdrawn upon the fulfillment of Integrity Israel’s severance obligations pursuant to Israeli severance pay laws or labor agreements with its employees. The value of the deposited funds was based on the cash surrender value of these policies, and includes immaterial profits or losses. Commencing in 2011, Integrity Israel’s agreements with its Israeli employees are in accordance with Section 14 of the Severance Pay Law. Payments in accordance with Section 14 release the employer from any future severance payments in respect of those employees. Related obligations and liabilities under Section 14 are not recorded as an asset or as a liability in the Company’s balance sheet. For the year ended December 31, 2022, and 2021, severance expenses have been recorded in total amount of $ 27 43
Research and development expenses	K. Research and development expenses Research and development expenses are charged to operations as incurred.
Royalty-bearing grants	L. Royalty-bearing grants Royalty-bearing grants from the Israeli Innovation Authority (IIA) to fund approved research and development projects are recognized at the time Integrity Israel is entitled to such grants, on the basis of the costs incurred and reduce research and development costs. To date, the cumulative research and development grants received by Integrity Israel from IIA amounted to $ 93 GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.) NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
Basic and diluted loss per share	M. Basic and diluted loss per share Basic loss per share is computed by dividing the loss for the period applicable for Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period. In computing, diluted loss per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon the exercise of options or warrants issued or granted using the “treasury stock method”, if the effect of each of such financial instruments is dilutive. In computing diluted loss per share, the average stock price for the period is used in determining the number of common stock assumed to be purchased from the exercise of stock options or stock warrants. Shares that will be issued upon exercise of all stock options and stock warrants, have been excluded from the calculation of the diluted net loss per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as a result of the exercise or conversion of these instruments was anti-dilutive An amount of 6,614,654 6,404,238
Stock-based compensation	N. Stock-based compensation The Group measures and recognizes the compensation expense for all equity-based payments to employees based on their estimated fair values in accordance with ASC 718, “Compensation-Stock Compensation”. Share-based payments including grants of stock options are recognized in the consolidated statement of operations and comprehensive loss as an operating expense based on the fair value of the award at the date of grant. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model. The Group has expensed compensation costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit service period when a performance condition affects the vesting, and it is considered probable that the performance condition will be achieved. Commencing January 1, 2019, following the adoption of ASU 2018-07, which aligns the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payments to employees (with certain exceptions), share-based payments to non-employees are accounted in accordance with ASC 718. GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.) NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
Fair value of financial instruments	O. Fair value of financial instruments ASC Topic 825-10, “Financial Instruments” defines financial instruments and requires disclosure of the fair value of financial instruments held by the Group. The Group considers the carrying amount of cash and cash equivalents, restricted cash, accounts receivable, other current assets, accounts payable and other current liabilities balances, to approximate their fair values due to the short-term maturities of such financial instruments. ASC Topic 825-10, establishes the following fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1 - Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2 - Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. Level 3 - Unobservable inputs are used when little or no market data is available. Level 3 inputs are considered as the lowest priority under the fair value hierarchy. The fair value of the financial instruments included in the working capital of the Group (cash and cash equivalents, accounts payable and other current assets and liabilities) approximates their carrying value. The Group did not estimate the fair value of the loans received from stockholders since their repayment schedule has not yet been determined.
Concentrations of credit risk	P. Concentrations of credit risk Financial instruments that potentially subject the Group to concentrations of credit risk consist primarily of cash and cash equivalents, and restricted cash. Cash and cash equivalents and restricted cash are deposited with major banks in United States. Management believes that such financial institutions are financially sound, accordingly, minimal credit risk exists with respect to these financial instruments. The Group does not have any significant off-balance-sheet concentration of credit risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.
Contingencies	Q. Contingencies The Group records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred.
Warrants with Down-Round Protection	R. Warrants with Down-Round Protection Following the application of Accounting Standard Update (ASU) No. 2017-11, “Earnings Per Share” (ASU 2017-11), the Company disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. Based on its evaluation, management has determined that such warrants with Down-Round Protection are eligible for equity classification. In accordance with the provisions of ASU 2017-11, upon the occurrence of an event that triggers a down round protection (i.e., when the exercise price of the warrants is adjusted downward because of the down round feature), the effect is accounted for as a deemed dividend and as a reduction of income available to common shareholders for purposes of basic earnings per share (EPS) calculation.
Modification of equity-classified contracts	S. Modification of equity-classified contracts The modification or exchange of equity-classified contracts, such as warrants that were classified as equity before the modification or exchange and remained eligible for equity classification after the modification, is accounted for in a similar manner to a modification of stock-based compensation. Accordingly, the incremental fair value from the modification or exchange (the change in the fair value of the instrument before and after the modification or exchange) is recognized as a reduction of retained earnings of increase of accumulated deficit as a deemed dividend. Modifications or exchanges that result in a decrease in the fair value of an equity-classified share-based payment awards are not recognized. In addition, the amount of the deemed dividend is also recognized as an adjustment to earnings available to common shareholders for purposes of calculating earnings per share. GLUCOTRACK INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (cont.) NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)
Operating Lease	T. Operating Lease The Company applies ASC Update 2016-02, Leases (Topic 842) under which the Company determines if an arrangement is a lease at inception. Under Topic 842, arrangements meeting the definition of a lease are classified as operating or financing leases. A classification of a lease is determined based on the following criteria: 1. The lease transfers ownership of the underlying asset to the lessee by the end of the lease term. 2. The lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise. 3. The lease term is for the major part of the remaining economic life of the underlying asset ( Generally, 75% or more of the remaining economic life of the underlying assets 4. The present value of the sum of the lease payments and any residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset ( Generally, 90% or more of the fair value of the underlying asset 5. The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. If any of the above criteria are met, the lease is classified as a finance lease. Otherwise, the lease is classified as an operating lease. Leases are recorded on the consolidated balance sheet as both a right of use asset and a lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset results in straight-line rent expense over the lease term. Variable lease expenses, if any, are recorded when incurred. The Company also elected the short-term lease recognition exemption for all leases that qualify (leases with a term shorter than 12 In 2022, the Company terminated its lease agreement for vehicles, as the senior employees in Israel has resigned from the Company, and respectively have returned the vehicles to the lease dealership. As of December 31, 2022, the Company is subject to several non-cancelable lease agreements for workspaces for use in its operations, which are classified as operating leases.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
SCHEDULE OF OFFICIAL EXCHANGE RATE	SCHEDULE OF OFFICIAL EXCHANGE RATE 2022 2021 Official exchange rate of NIS 1 to US dollar 0.284 0.321 Increase (decrease) of the official exchange rate of NIS 1 to US dollar during the year: ( 11.62 )% 3.22 %
SCHEDULE OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION	SCHEDULE OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION % Computers 33 Furniture and office equipment 7 15
SCHEDULE OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS	SCHEDULE OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS 2022 2021 In thousand of US dollars December 31 December 31 2022 2021 Cash and cash equivalents $ 2,312 $ 6,062 Restricted cash $ 19 $ 51 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 2,331 $ 6,113

PROPERTY AND EQUIPMENT, NET (Ta

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT, NET	SCHEDULE OF PROPERTY AND EQUIPMENT, NET Property and Equipment In thousand of US dollars December 31, 2022 December 31, 2021 Computers 224 306 Furniture and office equipment 70 183 Property and equipment, gross 294 489 Less – accumulated depreciation (254 ) (420 ) Property and equipment, net 40 69

OTHER CURRENT LIABILITIES (Tabl

OTHER CURRENT LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2022
Other Liabilities Disclosure [Abstract]
SCHEDULE OF OTHER CURRENT LIABILITIES	SCHEDULE OF OTHER CURRENT LIABILITIES Other Current Liabilities In thousand of US dollars December 31, 2022 December 31, 2021 Employees and related institutions 16 98 Accrued expenses and others 325 131 Total other current liabilities 341 229

COMMON STOCK AND WARRANTS WIT_2

COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Tables)	12 Months Ended
	Dec. 31, 2022
SCHEDULE OF SHARE OPTION ACTIVITY FOR EMPLOYEES AND MEMBERS	SCHEDULE OF SHARE OPTION ACTIVITY FOR EMPLOYEES AND MEMBERS Number of Share Options Weighted Average Exercise Price Weighted average remaining contractual life Intrinsic value $ (years) $ Outstanding as of December 31, 2020 128,297 64.46 5.42 - Granted 589,933 5.2 2.88 - Forfeited or expired (98,177 ) 64.64 - - Outstanding as of December 31, 2021 620,053 8.05 2.99 - Exercisable as of December 31, 2021 39,223 50.27 4.65 - Number of Share Options Weighted Average Exercise Price Weighted average remaining contractual life Intrinsic value $ (years) $ Outstanding as of December 31, 2021 620,053 8.05 2.99 - Granted 115,857 5.2 2.68 - Forfeited or expired - - - - Outstanding as of December 31, 2022 735,910 7.6 2.1 - Exercisable as of December 31, 2022 245,535 12.4 2.58 -
SCHEDULE OF OUTSTANDING AND EXERCISABLE SHARE OPTIONS	SCHEDULE OF OUTSTANDING AND EXERCISABLE SHARE OPTIONS Exercise price - $ Share options outstanding as of December 31, 2022 Weighted average remaining contractual term Share options exercisable as of December 31, 2022 Weighted average remaining contractual term (years) (years) 100.75 3,846 4.26 3,846 4.26 58.5 26,274 4.18 26,274 4.18 5.2 705,790 2.01 215,415 1.91 735,910 245,535
SCHEDULE OF ASSUMPTIONS USED TO VALUE OPTIONS	SCHEDULE OF ASSUMPTIONS USED TO VALUE OPTIONS 2022 2021 Year ended December 31 2022 2021 Volatility (%) 72.15 % 49.21 % Risk-free interest rate (%) 2.5 % 2.5 % Dividend yield (%) - - Expected life (years) 3 3 Exercise price ($) 5.2 5.2 Share price ($) 1.89 3.1 4.65
SCHEDULE OF TOTAL COMPENSATION COST EQUITY BASED AWARDS	SCHEDULE OF TOTAL COMPENSATION COST EQUITY BASED AWARDS Research and Development December 31, 2022 December 31, 2021 In thousand of US dollars Research and Development December 31, 2022 December 31, 2021 Research and development 92 38 General and administrative 395 223 Total compensation cost 487 261
Non-Employee [Member]
SCHEDULE OF OUTSTANDING AND EXERCISABLE SHARE OPTIONS	SCHEDULE OF OUTSTANDING AND EXERCISABLE SHARE OPTIONS Exercise price - $ Share options outstanding and exercisable December 31, 2022 Weighted average remaining contractual term (years) 70.2 665,411 1.01 46.8 665,411 1.01 23.4 665,411 1.01 6.5 13,398 0.63 5.2 290,679 2.11 3.35 4,068,497 1.56 6,368,807

RESEARCH AND DEVELOPMENT EXPE_2

RESEARCH AND DEVELOPMENT EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2022
Research and Development [Abstract]
SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES	SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES Research and Development December 31, 2022 December 31, In thousand of US dollars Research and Development December 31, 2022 December 31, Salaries and related expenses 749 916 Professional fees 1,124 337 Expenses due to slow inventory write-off - 321 Depreciation 20 32 Vehicle maintenance 12 42 Other 62 162 Total Research and Development Expense 1,967 1,810

MARKETING EXPENSES (Tables)

MARKETING EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2022
Marketing Expenses
SCHEDULE OF MARKETING EXPENSE	SCHEDULE OF MARKETING EXPENSE Selling and Marketing December 31, December 31, Salaries and related expenses - 22 Professional fees - 115 Other - 2 Total selling and marketing expense - 139

GENERAL AND ADMINISTRATIVE EX_2

GENERAL AND ADMINISTRATIVE EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2022
General And Administrative Expenses
SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES	SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES In thousand of US dollars General and Administrative December 31, December 31, Salaries and related expenses 617 608 Professional fees 1,281 1,224 Bad debt expense - 59 Vehicle maintenance 8 41 Depreciation 3 10 Insurance 457 97 Other 99 52 Total general and administrative expenses 2,465 2,091

INCOME TAX (Tables)

INCOME TAX (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
SCHEDULE OF INCOME TAX LOSS FOR THE YEAR	SCHEDULE OF INCOME TAX LOSS FOR THE YEAR 2022 2021 Year ended December 31 2022 2021 Domestic $ 3,528 $ 1,255 Foreign entity (Integrity Israel) 907 2,812 Total loss for the year 4,435 4,067
SCHEDULE OF DEFERRED TAX ASSETS	SCHEDULE OF DEFERRED TAX ASSETS Composition of deferred tax assets: 2022 2021 As of December 31 Composition of deferred tax assets: 2022 2021 Vacation accrual - 6 Research and development credits 174 - Net operating losses carry forwards 11,805 11,654 Net deferred tax asset before deferred tax liabilities and valuation allowance 11,979 11,660 Valuation allowance (11,979 ) (11,660 ) Net deferred tax assets - -

GENERAL (Details Narrative)

GENERAL (Details Narrative) - USD ($) $ in Thousands	Aug. 13, 2021	Dec. 31, 2022	Nov. 22, 2022	Dec. 31, 2021	Sep. 27, 2021	Dec. 31, 2020
Stockholders' equity, reverse stock split	1 for 13
Stockholders equity		$ 1,230		$ 5,155		$ 8,982
Accumulated deficit		101,901		97,466
Cash and cash equivalents		$ 2,312		$ 6,062
Minimum [Member]
Stockholders equity			$ 2,500
Maximum [Member]
Debt securities					$ 100,000

SCHEDULE OF OFFICIAL EXCHANGE R

SCHEDULE OF OFFICIAL EXCHANGE RATE (Details)	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Official exchange rate of NIS 1 to US dollar	0.284	0.321
Increase (decrease) of the Official exchange rate of NIS 1 to US dollar during the year	0.1162	0.0322

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT, RATES OF DEPRECIATION (Details)	12 Months Ended
	Dec. 31, 2022
Computers [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment depreciation rate	33%
Furniture and Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment depreciation rate	7%
Furniture and Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment depreciation rate	15%

SCHEDULE OF RESTRICT CASH BALAN

SCHEDULE OF RESTRICT CASH BALANCES ARE INCLUDED WITH CASH AND CASH EQUIVALENTS (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Cash and cash equivalents	$ 2,312	$ 6,062
Restricted cash	19	51
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$ 2,331	$ 6,113	$ 9,885

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating Loss Carryforwards [Line Items]
Severance expenses	$ 27	$ 43
Cumulative research and development	$ 1,967	$ 1,810
Lease description	Generally, 75% or more of the remaining economic life of the underlying assets
Operating lease description	Generally, 90% or more of the fair value of the underlying asset
Lessor, Operating Lease, Term of Contract	12 months
Outstanding Stock Option and Warrants [Member]
Operating Loss Carryforwards [Line Items]
Antidilutive, shares	6,614,654	6,404,238
Israel Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Cumulative research and development	$ 93

SCHEDULE OF PROPERTY AND EQUI_2

SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 294	$ 489
Less - accumulated depreciation	(254)	(420)
Property and equipment, net	40	69
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	224	306
Furniture and Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 70	$ 183

PROPERTY AND EQUIPMENT, NET (De

PROPERTY AND EQUIPMENT, NET (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation	$ 23	$ 42

SCHEDULE OF OTHER CURRENT LIABI

SCHEDULE OF OTHER CURRENT LIABILITIES (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Other Liabilities Disclosure [Abstract]
Employees and related institutions	$ 16	$ 98
Accrued expenses and others	325	131
Total other current liabilities	$ 341	$ 229

LOANS FROM STOCKHOLDERS (Detail

LOANS FROM STOCKHOLDERS (Details Narrative) - USD ($) $ in Thousands	12 Months Ended	24 Months Ended
	Dec. 31, 2022	Dec. 31, 2004
Line of Credit Facility [Line Items]
Sales percent	10%
Four Separate Lenders [Member] | ISRAEL
Line of Credit Facility [Line Items]
Total loan amount		$ 400
Repayment of loan		$ 195

COMMITMENTS AND CONTINGENT LI_2

COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) ₪ in Thousands, $ in Thousands	Oct. 07, 2022 shares	Mar. 04, 2004 USD ($)	Dec. 31, 2022 USD ($)	Mar. 04, 2005 USD ($)	Mar. 04, 2004 ILS (₪)
Intellectual Property Purchase Agreement [Member] | Common Stock [Member]
Loss Contingencies [Line Items]
Number of common shares issued	1,000,000
Israeli Innovation Authority [Member]
Loss Contingencies [Line Items]
Royalty payment | $			$ 80	$ 93
Minimum [Member] | Intellectual Property Purchase Agreement [Member] | Common Stock [Member]
Loss Contingencies [Line Items]
Number of common shares issued	1,000,000
Commission as a percentage of aggregate sales price	1.50%
Minimum [Member] | Intellectual Property Purchase Agreement [Member] | Common Stock [Member] | Trueup Shares [Member]
Loss Contingencies [Line Items]
Commission as a percentage of aggregate sales price	1.50%
Israeli Innovation Authority [Member]
Loss Contingencies [Line Items]
Royalty payment		$ 93			₪ 420
Israeli Innovation Authority [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Royalty percent		3%
Israeli Innovation Authority [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Royalty percent		5%

SCHEDULE OF SHARE OPTION ACTIVI

SCHEDULE OF SHARE OPTION ACTIVITY FOR EMPLOYEES AND MEMBERS (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Number outstanding beginning balance	620,053	128,297
Weighted average exercise price outstanding, beginning balance	$ 8.05	$ 64.46
Weighted average remaining contractual life, Outstanding	2 years 1 month 6 days	2 years 11 months 26 days	5 years 5 months 1 day
Weighted average exercise price outstanding, beginning balance
Number shares, grants	115,857	589,933
Weighted average exercise price, granted	$ 5.2	$ 5.2
Weighted average remaining contractual life, Granted		2 years 10 months 17 days
Weighted average exercise price outstanding, beginning balance
Number, forfeited		(98,177)
Weighted average exercise price, forfeited		$ 64.64
Weighted average remaining contractual life, Forfeited or expired
Weighted average exercise price outstanding, beginning balance
Number outstanding ending balance	735,910	620,053	128,297
Weighted average exercise price outstanding, ending balance	$ 7.6	$ 8.05	$ 64.46
Weighted average exercise price outstanding, Ending balance
Number exercisable, ending balance	245,535	39,223
Weighted average exercise price exercisable, beginning balance	$ 12.4	$ 50.27
Weighted average remaining contractual life, Exercisable	2 years 6 months 29 days	4 years 7 months 24 days
Weighted average exercise price outstanding, Ending balance
Weighted average remaining contractual life, Granted	2 years 8 months 4 days

SCHEDULE OF OUTSTANDING AND EXE

SCHEDULE OF OUTSTANDING AND EXERCISABLE SHARE OPTIONS (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share options outstanding	735,910
Weighted average remaining contractual life	2 years 1 month 6 days	2 years 11 months 26 days	5 years 5 months 1 day
Weighted average remaining contractual life	2 years 8 months 4 days
Share options outstanding	245,535
Non-Employee [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Share options outstanding and exercisable	6,368,807
Exercise Price One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 100.75
Share options outstanding	3,846
Weighted average remaining contractual life	4 years 3 months 3 days
Weighted average remaining contractual life	4 years 3 months 3 days
Exercise Price One [Member] | Non-Employee [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 70.2
Weighted average remaining contractual life	1 year 3 days
Share options outstanding and exercisable	665,411
Exercise Price Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 58.5
Share options outstanding	26,274
Weighted average remaining contractual life	4 years 2 months 4 days
Weighted average remaining contractual life	4 years 2 months 4 days
Exercise Price Two [Member] | Non-Employee [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 46.8
Weighted average remaining contractual life	1 year 3 days
Share options outstanding and exercisable	665,411
Exercise Price Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 5.2
Share options outstanding	705,790
Weighted average remaining contractual life	2 years 3 days
Weighted average remaining contractual life	1 year 10 months 28 days
Share options outstanding	215,415
Exercise Price Three [Member] | Non-Employee [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 23.4
Weighted average remaining contractual life	1 year 3 days
Share options outstanding and exercisable	665,411
Exercise Price Four [Member] | Non-Employee [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 6.5
Weighted average remaining contractual life	7 months 17 days
Share options outstanding and exercisable	13,398
Exercise Price Five [Member] | Non-Employee [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 5.2
Weighted average remaining contractual life	2 years 1 month 9 days
Share options outstanding and exercisable	290,679
Exercise Price Six [Member] | Non-Employee [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price	$ 3.35
Weighted average remaining contractual life	1 year 6 months 21 days
Share options outstanding and exercisable	4,068,497

SCHEDULE OF ASSUMPTIONS USED TO

SCHEDULE OF ASSUMPTIONS USED TO VALUE OPTIONS (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Volatility (%)	72.15%	49.21%
Risk-free interest rate (%)	2.50%	2.50%
Dividend yield (%)
Expected life (years)	3 years	3 years
Expected life (years)	$ 5.2	$ 5.2
Share price	$ 1.89
Minimum [Member]
Share price		3.1
Maximum [Member]
Share price		$ 4.65

SCHEDULE OF TOTAL COMPENSATION

SCHEDULE OF TOTAL COMPENSATION COST EQUITY BASED AWARDS (Details) - Research and Development Arrangement [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Long-Term Purchase Commitment [Line Items]
Total compensation cost	$ 487	$ 261
Research and Development Expense [Member]
Long-Term Purchase Commitment [Line Items]
Total compensation cost	92	38
General and Administrative Expense [Member]
Long-Term Purchase Commitment [Line Items]
Total compensation cost	$ 395	$ 223

COMMON STOCK AND WARRANTS WIT_3

COMMON STOCK AND WARRANTS WITH-DOWN ROUND PROTECTION (Details Narrative) $ / shares in Units, ₪ in Thousands, shares in Thousands, $ in Thousands

1 Months Ended

12 Months Ended

Sep. 12, 2022 USD ($)

May 31, 2022 shares

Dec. 20, 2021 shares

Nov. 30, 2021 USD ($) $ / shares shares

Feb. 08, 2021 USD ($) $ / shares

Feb. 08, 2021 ILS (₪)

Nov. 30, 2020 USD ($) $ / shares

Nov. 30, 2020 ILS (₪)

Jan. 11, 2010

Oct. 31, 2022 USD ($) $ / shares shares

Dec. 31, 2021 USD ($) $ / shares

Aug. 31, 2020 USD ($) $ / shares shares

Dec. 31, 2022 USD ($) $ / shares shares

Dec. 31, 2021 USD ($) $ / shares shares

Dec. 31, 2017 $ / shares shares

Feb. 29, 2020 $ / shares shares

Accumulated Other Comprehensive Income (Loss) [Line Items]

Plan description

the Company’s Board of Directors has full authority in its discretion, from time to time and at any time, to determine (i) the designate participants; (ii) the terms and provisions of the respective award agreements, including, but not limited to, the number of share options to be granted to each optionee, the number of shares to be covered by each share option, provisions concerning the time and the extent to which the share options may be exercised and the nature and duration of restrictions as to the transferability or restrictions constituting substantial risk of forfeiture and to cancel or suspend awards, as necessary; (iii) determine the fair market value of the shares covered by each award; (iv) make an election as to the type of approved 102 Option under Israeli tax law; (v) designate the type of share options; (vi) take any measures, and to take actions, as deemed necessary or advisable for the administration and implementation of the Plan; (vii) interpret the provisions of the Plan and to amend from time to time the terms of the Plan

Par value

$ 0.001

$ 0.001

$ 0.001

Number of options | shares

115,857

589,933

Compensartion | $

$ 186

Contractual term

8 months 19 days

Andrew Garrett Inc [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Compensation | $

$ 56

Terms of award

the Company has issued to Andrew Garrett Inc, who served as a placement agent in fundraising transaction (a) 5-year warrants to purchase up to 1,062,717 shares of Common Stock at an exercise price of $3.354 per share, (b) 5-year warrants to purchase up to 108,305 shares of Common Stock at an exercise price of $23.40 per share, (c) 5-year warrants to purchase up to 8,331 shares of Common Stock at an exercise price of $46.80 per share and (d) 5-year warrants to purchase up to 8,331 shares of Common Stock at an exercise price of $70.20 per share

Andrew Garrett Inc [Member] | Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrant term

5 years

Warrant purchase, shares | shares

288,462

Exercise price

$ 5.2

Andrew Garrett Inc [Member] | Share-Based Payment Arrangement, Tranche One [Member] | Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrant term

5 years

Warrant purchase, shares | shares

1,062,717

Exercise price

$ 3.354

Andrew Garrett Inc [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrant term

5 years

Warrant purchase, shares | shares

108,305

Exercise price

$ 23.40

Andrew Garrett Inc [Member] | Share-Based Payment Arrangement, Tranche Three [Member] | Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrant term

5 years

Warrant purchase, shares | shares

8,331

Exercise price

$ 46.80

Andrew Garrett Inc [Member] | Share Based Compensation Award Tranche Four [Member] | Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrant term

5 years

Warrant purchase, shares | shares

8,331

Exercise price

$ 70.20

McGuire & Assoc. LLC [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock based compensation expenses | $

$ 9

$ 13

Cash fee | $

$ 4

McGuire & Assoc. LLC [Member] | Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrant purchase, shares | shares

461

Exercise price

$ 6.5

Restricted Stock Units (RSUs) [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share price

$ 5.20

Erez Ben Zvi [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock based compensation expenses | $

25

76

Erez Ben Zvi [Member] | Restricted Stock Units (RSUs) [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Compensation

$ 65

₪ 210

Terms of award

1/12 of the RSUs shall vest and become nonforfeitable three months following the Start Date, and an additional 1/12 of the RSUs shall vest and become nonforfeitable at the end of every 3-months period thereafter, provided that the employee continues to be employed by the Company at the applicable date of vesting

1/12 of the RSUs shall vest and become nonforfeitable three months following the Start Date, and an additional 1/12 of the RSUs shall vest and become nonforfeitable at the end of every 3-months period thereafter, provided that the employee continues to be employed by the Company at the applicable date of vesting

Shalom Shushan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock based compensation expenses | $

6

22

Shalom Shushan [Member] | Restricted Stock Units (RSUs) [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Compensation

$ 484

$ 28

₪ 90

Share price

$ 5.20

Terms of award

1/12 of the RSUs shall vest and become nonforfeitable three months following the Start Date, and an additional 1/12 of the RSUs shall vest and become nonforfeitable at the end of every 3-months period thereafter, provided that the Employee continues to be employed by the Company at the applicable date of vesting

1/12 of the RSUs shall vest and become nonforfeitable three months following the Start Date, and an additional 1/12 of the RSUs shall vest and become nonforfeitable at the end of every 3-months period thereafter, provided that the Employee continues to be employed by the Company at the applicable date of vesting

Shalom Shushan [Member] | Restricted Stock Units (RSUs) [Member] | Employee [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Compensation | ₪

₪ 60

Mr Paul V [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share price

$ 5.20

Stock based compensation expenses | $

306

$ 98

Diluted percent

1.50%

Par value

$ 0.001

Number of options | shares

18,000

328

Mr James P [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share price

$ 5.20

$ 5.20

Stock based compensation expenses | $

93

$ 16

Diluted percent

1.15%

1.15%

Par value

$ 0.001

$ 0.001

Number of options | shares

262

Mr James P [Member] | Restricted Stock Units (RSUs) [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Compensation | $

$ 152

Mark Tapsak [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share price

$ 5.20

Stock based compensation expenses | $

$ 5

Diluted percent

0.75%

Par value

$ 0.001

Mark Tapsak [Member] | Restricted Stock Units (RSUs) [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Compensation | $

$ 22

Number of options | shares

116

SCHEDULE OF RESEARCH AND DEVELO

SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Total Research and Development Expense	$ 1,967	$ 1,810
Salaries And Related [Member]
Total Research and Development Expense	749	916
Professional Fees
Total Research and Development Expense	1,124	337
Expenses Due To Slow Inventory [Member]
Total Research and Development Expense		321
Depreciation
Total Research and Development Expense	20	32
Vehicle Maintenance [Member]
Total Research and Development Expense	12	42
Other Expense [Member]
Total Research and Development Expense	$ 62	$ 162

SCHEDULE OF MARKETING EXPENSE (

SCHEDULE OF MARKETING EXPENSE (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Other		$ 139
Total selling and marketing expense		139
Salaries And Related [Member]
Other		22
Total selling and marketing expense		22
Professional Fees
Other		115
Total selling and marketing expense		115
Other Expense [Member]
Other		2
Total selling and marketing expense		$ 2

SCHEDULE OF GENERAL AND ADMINIS

SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Total general and administrative expenses	$ 2,465	$ 2,091
General and Administrative Expense [Member]
Salaries and related expenses	617	608
Professional fees	1,281	1,224
Bad debt expense		59
Vehicle maintenance	8	41
Depreciation	3	10
Insurance	457	97
Other	99	52
Total general and administrative expenses	$ 2,465	$ 2,091

SCHEDULE OF INCOME TAX LOSS FOR

SCHEDULE OF INCOME TAX LOSS FOR THE YEAR (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Domestic	$ 3,528	$ 1,255
Foreign entity (Integrity Israel)	907	2,812
Total loss for the year	$ 4,435	$ 4,067

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Vacation accrual		$ 6
Research and development credits	174
Net operating losses carry forwards	11,805	11,654
Net deferred tax asset before deferred tax liabilities and valuation allowance	11,979	11,660
Valuation allowance	(11,979)	(11,660)
Net deferred tax assets

INCOME TAX (Details Narrative)

INCOME TAX (Details Narrative) $ in Millions	Dec. 31, 2022 USD ($)
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 14
Israel Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 38

SEGMENT INFORMATION (Details Na

SEGMENT INFORMATION (Details Narrative)	12 Months Ended
	Dec. 31, 2022 Segment
Segment Reporting [Abstract]
Segments	1

RELATED PARTIES (Details Narrat

RELATED PARTIES (Details Narrative) - USD ($) $ in Thousands			12 Months Ended
	Oct. 25, 2022	Sep. 12, 2022	Dec. 31, 2022
Mark Tapsak [Member]
Related Party Transaction [Line Items]
Consideration	$ 60
Mark Tapsak [Member] | Tapsak Enterprises LLC [Member]
Related Party Transaction [Line Items]
Total related parties expenses			$ 38
Andrew Garrett Inc [Member]
Related Party Transaction [Line Items]
Consideration		$ 20
Total related parties expenses			$ 102
Andrew Garrett Inc [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Consideration		$ 56